The Xen45 gel stent showed promising short-term safety and efficacy in patients with refractory glaucoma, according to a poster presented at the virtual Association for Research in Vision and Ophthalmology meeting.
“Decreased efficacy at 6 months may be due to the smaller sample size available at that time point,” Alexander B. Crane said.
The Xen gel stent (Allergan) consists of a 6-mm hydrophilic tube made of collagen-derived gelatin cross-linked with glutaraldehyde, is non-inflammatory and is theorized to cause minimal tissue response. It is injected in the subconjunctival space,
Uncategorized